Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

Andrea De Luca; David Dunn; Maurizio Zazzi; Ricardo Camacho; Carlo Torti; Iuri Fanti; Rolf Kaiser; Anders Sönnerborg; Francisco M. Codoñer; Kristel Van Laethem; Anne-Mieke Vandamme; Loveleen Bansi; Valeria Ghisetti; David A.M.C. Van De Vijver; David Asboe; Mattia C.F. Prosperi; Simona Di Giambenedetto

doi:10.1093/infdis/jit017

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

Andrea De Luca, David Dunn, Maurizio Zazzi, Ricardo Camacho, Carlo Torti, Iuri Fanti, Rolf Kaiser, Anders Sönnerborg, Francisco M. Codoñer, Kristel Van Laethem, Anne-Mieke Vandamme, Loveleen Bansi, Valeria Ghisetti, David A.M.C. Van De Vijver, David Asboe, Mattia C.F. Prosperi, Simona Di Giambenedetto

Risultato della ricerca: Contributo in rivista › Articolo in rivista

47 Citazioni (Scopus)

Abstract

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.

Lingua originale	English
pagine (da-a)	N/A-N/A
Rivista	THE JOURNAL OF INFECTIOUS DISEASES
DOI	https://doi.org/10.1093/infdis/jit017
Stato di pubblicazione	Pubblicato - 2013

Keywords

Drug Resistance Prevalence HIV-1

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1093/infdis/jit017

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

De Luca, A., Dunn, D., Zazzi, M., Camacho, R., Torti, C., Fanti, I., Kaiser, R., Sönnerborg, A., Codoñer, F. M., Van Laethem, K., Vandamme, A.-M., Bansi, L., Ghisetti, V., Van De Vijver, D. A. M. C., Asboe, D., Prosperi, M. C. F., & Di Giambenedetto, S. (2013). Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe. THE JOURNAL OF INFECTIOUS DISEASES, N/A-N/A. https://doi.org/10.1093/infdis/jit017

@article{f59b108e9b474187b59a65ec15077166,

title = "Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe",

abstract = "HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.",

keywords = "Drug Resistance Prevalence HIV-1, Drug Resistance Prevalence HIV-1",

author = "{De Luca}, Andrea and David Dunn and Maurizio Zazzi and Ricardo Camacho and Carlo Torti and Iuri Fanti and Rolf Kaiser and Anders S{\"o}nnerborg and Codo{\~n}er, {Francisco M.} and {Van Laethem}, Kristel and Anne-Mieke Vandamme and Loveleen Bansi and Valeria Ghisetti and {Van De Vijver}, {David A.M.C.} and David Asboe and Prosperi, {Mattia C.F.} and {Di Giambenedetto}, Simona",

year = "2013",

doi = "10.1093/infdis/jit017",

language = "English",

pages = "N/A--N/A",

journal = "THE JOURNAL OF INFECTIOUS DISEASES",

issn = "0022-1899",

publisher = "University of Chicago Press:PO Box 37005, Journals Division:Chicago, IL 60637:(877)705-1878, (877)705-1878, (773)753-2247, EMAIL: [email protected], INTERNET: http://www.press.uchicago.edu, Fax: (877)705-1879, (773)753-0811",

}

De Luca, A, Dunn, D, Zazzi, M, Camacho, R, Torti, C, Fanti, I, Kaiser, R, Sönnerborg, A, Codoñer, FM, Van Laethem, K, Vandamme, A-M, Bansi, L, Ghisetti, V, Van De Vijver, DAMC, Asboe, D, Prosperi, MCF & Di Giambenedetto, S 2013, 'Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe', THE JOURNAL OF INFECTIOUS DISEASES, pagg. N/A-N/A. https://doi.org/10.1093/infdis/jit017

TY - JOUR

T1 - Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

AU - De Luca, Andrea

AU - Dunn, David

AU - Zazzi, Maurizio

AU - Camacho, Ricardo

AU - Torti, Carlo

AU - Fanti, Iuri

AU - Kaiser, Rolf

AU - Sönnerborg, Anders

AU - Codoñer, Francisco M.

AU - Van Laethem, Kristel

AU - Vandamme, Anne-Mieke

AU - Bansi, Loveleen

AU - Ghisetti, Valeria

AU - Van De Vijver, David A.M.C.

AU - Asboe, David

AU - Prosperi, Mattia C.F.

AU - Di Giambenedetto, Simona

PY - 2013

Y1 - 2013

N2 - HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.

AB - HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.

KW - Drug Resistance Prevalence HIV-1

UR - http://hdl.handle.net/10807/39905

U2 - 10.1093/infdis/jit017

DO - 10.1093/infdis/jit017

M3 - Article

SN - 0022-1899

SP - N/A-N/A

JO - THE JOURNAL OF INFECTIOUS DISEASES

JF - THE JOURNAL OF INFECTIOUS DISEASES

ER -

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo